X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need with MD Anderson responsible for leading initial Phase 1/2 studies.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 16, 2024
Details:
Flu mRNA (GSK4382276A) is a intramuscularly administered mRNA-based multivalent seasonal influenza vaccine, which is being evaluated for the treatment of seasonal influenza.
Lead Product(s): GSK4382276A
Therapeutic Area: Infections and Infectious Diseases Product Name: Flu mRNA
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
CV0701 is a biovalent vaccine candidate, which encodes the spike protein of the omicron BA.4-5 variant and it is under phase 2 clinical development for the treatment of Covid-19 infection.
Lead Product(s): CV0701
Therapeutic Area: Infections and Infectious Diseases Product Name: CV0701
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
The monovalent candidate, CV0601, encodes the spike protein of the omicron BA.4-5 variant and is being developed in collaboration with GSK
Lead Product(s): CV0601
Therapeutic Area: Infections and Infectious Diseases Product Name: CV0601
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
CVGBM is CureVac's first investigational cancer vaccine based on its proprietary second-generation mRNA backbone designed for improved mRNA translation and increased as well as extended protein expression, which is investigated for the treatment of Glioblastoma.
Lead Product(s): CVGBM
Therapeutic Area: Oncology Product Name: CVGBM
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
GSK4382276A is a mRNA seasonal flu vaccine which activates immunization for the prevention of disease caused by influenza viruses in adults 18 years and above.
Lead Product(s): GSK4382276A
Therapeutic Area: Infections and Infectious Diseases Product Name: GSK4382276A
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
CV0501 (mRNA-based prophylactic vaccine) is a monovalent mRNA vaccine candidate using modified nucleosides, encoding the S protein of Omicron BA.1 and maintaining the same pre-fusion stabilizing mutations in S protein.
Lead Product(s): mRNA-based Prophylactic Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CV0501
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 10, 2023
Details:
The Company intends to use the net proceeds from the offering primarily for the development of CV0501(mRNA-based prophylactic vaccine), and for general corporate purposes.
Lead Product(s): mRNA-based Prophylactic Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CV0501
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 07, 2023
Details:
CV0501 is the first COVID-19 vaccine candidate applying chemically modified mRNA from the COVID-19. It encodes the prefusion stabilized full-length spike protein of the SARS-CoV-2 Omicron variant BA.1 and is formulated with lipid nanoparticles (LNPs).
Lead Product(s): CV0501
Therapeutic Area: Infections and Infectious Diseases Product Name: CV0501
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
CV0501 was designed with specifically optimized non-coding regions aiming to deliver improved mRNA translation for increased and extended protein expression compared to the first-generation mRNA backbone.
Lead Product(s): CV0501
Therapeutic Area: Infections and Infectious Diseases Product Name: CV0501
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
